Last updated: September 24, 2026
Daunorubicin hydrochloride is a mature anthracycline used primarily in combination regimens for acute myeloid leukemia and acute lymphoblastic leukemia. Its commercial profile is defined by generic competition, low unit pricing, hospital procurement, intermittent supply constraints, and limited patent protection. The molecule has little standalone growth potential, but demand remains clinically durable because it is embedded in established leukemia protocols and is difficult to remove from treatment pathways without substituting another anthracycline.
What is the current market position of daunorubicin hydrochloride?
Daunorubicin hydrochloride is an injectable cytotoxic medicine administered intravenously. It is used mainly as part of combination chemotherapy rather than as a high-value branded monotherapy.
| Market characteristic |
Assessment |
| Primary therapeutic areas |
Acute myeloid leukemia, acute lymphoblastic leukemia |
| Drug class |
Anthracycline topoisomerase II inhibitor |
| Dosage form |
Sterile injectable powder or solution for intravenous use |
| Commercial status |
Mature generic hospital product |
| Branded originator |
Cerubidine |
| Regulatory status |
FDA-approved product category with generic availability |
| Patent position |
No meaningful remaining composition-of-matter exclusivity |
| Pricing power |
Low |
| Main buyers |
Hospitals, group purchasing organizations, oncology distributors |
| Key commercial risks |
Manufacturing concentration, shortages, low generic margins |
| Growth profile |
Stable to declining in value, with durable clinical demand |
The drug’s value is linked to treatment volume, not brand differentiation. Physicians can substitute among anthracycline-based regimens in selected settings, but daunorubicin remains a standard component of induction therapy for acute myeloid leukemia and selected acute lymphoblastic leukemia protocols. FDA labeling identifies its use in combination chemotherapy for acute nonlymphocytic leukemia and acute lymphocytic leukemia (U.S. Food and Drug Administration [FDA], n.d.-a).
How does daunorubicin hydrochloride generate revenue?
Revenue comes from hospital and institutional sales of generic vials. Public companies generally do not report daunorubicin hydrochloride revenue as a separate line item, and the original branded product does not provide a reliable current benchmark for market value.
The product’s financial trajectory has four stages:
- Originator phase: Daunorubicin was commercialized as Cerubidine and established as an anthracycline chemotherapy product.
- Generic transition: Patent and regulatory exclusivity expired decades ago, allowing multiple manufacturers to enter.
- Commodity phase: Pricing shifted toward tendering, group purchasing, and hospital contract competition.
- Supply-constrained maturity: Shortages and manufacturer exits can raise transaction prices temporarily, but they do not create durable branded pricing power.
The commercial value of a single manufacturer depends more on contract access and supply reliability than on intellectual property. A manufacturer with an approved sterile injectable facility, validated cytotoxic containment, and reliable active pharmaceutical ingredient sourcing can maintain share even without patent protection.
What are the main demand drivers for daunorubicin hydrochloride?
Demand is driven by leukemia incidence, treatment guidelines, hospital chemotherapy volumes, and the persistence of anthracycline-containing induction regimens.
Acute myeloid leukemia
Daunorubicin is commonly paired with cytarabine in intensive induction therapy for eligible patients with acute myeloid leukemia. The conventional "7+3" regimen uses continuous-infusion cytarabine for seven days and an anthracycline, commonly daunorubicin, for three days. Dose selection varies by protocol, patient age, fitness, disease biology, and institutional practice.
The introduction of targeted agents has changed some acute myeloid leukemia regimens but has not eliminated anthracycline use. FLT3 inhibitors, IDH inhibitors, and venetoclax-based combinations have expanded treatment options. Intensive chemotherapy remains relevant for patients who are fit for induction and may proceed to allogeneic stem-cell transplantation.
Acute lymphoblastic leukemia
Daunorubicin is also used in multi-agent acute lymphoblastic leukemia protocols, particularly during induction or consolidation phases. Use varies by age group and protocol. Pediatric and adolescent treatment programs may continue to use anthracycline-containing regimens, while adult practice is more heterogeneous.
Protocol durability
Demand is relatively resistant to short-term clinical substitution because chemotherapy protocols are embedded in hospital pathways, clinical guidelines, and pharmacy compounding systems. Volume can decline when lower-intensity regimens expand, but the drug remains relevant in intensive treatment.
What is the FDA regulatory status of daunorubicin hydrochloride?
Daunorubicin hydrochloride is an FDA-approved prescription oncology product administered in a hospital or specialist treatment setting. The product is generally supplied as an injectable vial and carries boxed warnings related to cardiotoxicity, severe myelosuppression, tissue necrosis from extravasation, and other serious risks.
The FDA labeling requires attention to cumulative anthracycline exposure and cardiac function. These safety requirements support continued use in medically supervised settings and limit any shift toward retail pharmacy distribution (FDA, n.d.-a).
Orange Book status
The Orange Book does not provide a meaningful exclusivity barrier for the mature generic daunorubicin hydrochloride injection market. The original innovator exclusivity period expired many years ago. Current competition is therefore governed mainly by abbreviated new drug application approvals, manufacturing capacity, procurement contracts, and supply continuity.
No active composition-of-matter exclusivity should be expected to protect the base daunorubicin hydrochloride molecule in the United States. Product-specific formulation or manufacturing patents would need to be assessed at the individual abbreviated application level, but they do not appear to create a broad market barrier for standard daunorubicin hydrochloride injection.
What patents protect daunorubicin hydrochloride?
The base molecule has no commercially relevant remaining U.S. composition patent estate. Daunorubicin was discovered and developed in the 1960s, placing it far beyond ordinary small-molecule patent terms.
| Patent category |
Current commercial relevance |
| Composition of matter |
No meaningful remaining protection |
| Basic therapeutic use |
Historical protection expired |
| Standard injectable formulation |
Generally open to generic competition |
| Manufacturing process |
Possible company-specific know-how; limited market exclusion |
| Liposomal delivery |
Separate product and patent analysis required |
| Fixed-ratio combination products |
Separate patents may apply |
Manufacturing know-how remains commercially relevant even when it is not patent-protected. Sterile injectable oncology products require validated processes, container-closure controls, stability data, and hazardous-drug handling systems. These operational barriers can reduce the number of active suppliers without creating formal exclusivity.
When does daunorubicin hydrochloride lose exclusivity?
Daunorubicin hydrochloride lost meaningful U.S. market exclusivity decades ago. There is no current exclusivity cliff comparable to a modern branded oncology product.
The relevant commercial dates are therefore not patent expiration dates but:
- Generic approval dates
- Manufacturer entry and withdrawal dates
- Supply shortage periods
- Contract renewal cycles
- FDA manufacturing observations or remediation events
- Changes in leukemia treatment guidelines
This distinction matters for investors. A patent-expiration model would materially overstate the market opportunity because the product is already in the post-exclusivity commodity phase.
Are there Paragraph IV challenges or patent litigation affecting daunorubicin?
No major, current Paragraph IV litigation involving standard daunorubicin hydrochloride injection is a central market issue. The drug’s age and generic status make a conventional patent challenge unlikely to drive market timing.
The more relevant legal risks are operational:
- Contract disputes over supply or allocation
- Product liability claims involving extravasation or cardiotoxicity
- FDA enforcement involving sterile manufacturing
- Recalls caused by contamination, particulate matter, potency, or labeling
- Disputes involving combination or liposomal products rather than standard daunorubicin
A Paragraph IV strategy would have limited value unless a manufacturer identified a specific, enforceable patent covering a new formulation, delivery system, or manufacturing method. The standard injectable product has no obvious patent-based launch barrier.
What formulations of daunorubicin are protected?
Standard daunorubicin hydrochloride injection is not a strong formulation-patent opportunity. The commercial differentiation lies in delivery technology, fixed combinations, or improved administration rather than in the conventional vial.
Liposomal daunorubicin
Liposomal daunorubicin products have a separate regulatory and patent history. DaunoXome, a liposomal formulation of daunorubicin citrate, was developed for AIDS-related Kaposi sarcoma. Its clinical and commercial profile differs from standard daunorubicin hydrochloride injection because the lipid carrier changes distribution, dosing, and administration.
A liposomal product cannot automatically be treated as an interchangeable generic version of conventional daunorubicin hydrochloride. It requires separate regulatory support and may face different patent, clinical, and manufacturing considerations.
Fixed-ratio combinations
The most important differentiated daunorubicin product is CPX-351, marketed as Vyxeos. It is a liposomal fixed-ratio combination of daunorubicin and cytarabine approved for therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes. Jazz Pharmaceuticals acquired Celator Pharmaceuticals, the developer of Vyxeos, in 2016, giving it commercial control of the product (Jazz Pharmaceuticals, 2016; FDA, n.d.-b).
Vyxeos is not a direct generic equivalent to standard daunorubicin hydrochloride. Its value proposition is based on a defined 5:1 molar ratio and liposomal delivery. This creates a higher-value commercial segment while leaving standard daunorubicin exposed to generic pricing.
How does daunorubicin compare with competing anthracyclines?
| Product |
Main role |
Commercial position |
Differentiation |
| Daunorubicin HCl |
Leukemia induction and combination chemotherapy |
Mature generic |
Low price, established protocols |
| Doxorubicin HCl |
Broad oncology use |
Large generic market |
Wider tumor coverage |
| Idarubicin HCl |
Acute myeloid leukemia and other hematologic use |
Generic |
Greater lipophilicity and protocol-specific use |
| Liposomal doxorubicin |
Ovarian cancer, myeloma, Kaposi sarcoma |
Higher-value specialty generic/brand segment |
Altered pharmacokinetics and toxicity profile |
| CPX-351/Vyxeos |
Selected secondary or therapy-related AML |
Branded specialty product |
Liposomal fixed-ratio combination |
| Mitoxantrone |
Hematologic malignancies and other uses |
Generic |
Non-anthracycline topoisomerase II inhibitor |
Doxorubicin has a broader oncology market, giving it greater aggregate commercial importance. Idarubicin competes more directly in acute myeloid leukemia but is not always clinically interchangeable. CPX-351 competes for selected acute myeloid leukemia patients but is positioned as a differentiated regimen rather than a low-cost vial substitute.
What is the financial trajectory for daunorubicin hydrochloride?
The base product has a mature, low-growth financial profile.
Revenue outlook
Public revenue data for standard daunorubicin hydrochloride are limited because manufacturers generally include the product in broader hospital injectable or generic oncology portfolios. The likely trajectory is:
| Period |
Financial characteristics |
| Historical branded period |
Higher margins and originator control |
| Early generic period |
Rapid price erosion and supplier expansion |
| Mature generic period |
Low unit prices and stable clinical volume |
| Shortage periods |
Temporary price increases and allocation premiums |
| Long term |
Flat or declining nominal revenue, with episodic supply-driven spikes |
Volume should remain relatively durable because leukemia treatment demand persists. Revenue is more vulnerable than volume because of generic price competition and procurement pressure.
Margin profile
Margins depend on:
- Active pharmaceutical ingredient costs
- Sterile fill-finish capacity
- Vial and packaging costs
- Quality-control requirements
- Hazardous-drug containment
- Hospital contract pricing
- Supply allocation and inventory carrying costs
A manufacturer with excess sterile injectable capacity may accept low margins to retain a broader hospital portfolio. A manufacturer facing remediation, batch failures, or raw-material disruption may exit despite continued clinical demand.
What supply-chain risks affect the market?
Daunorubicin hydrochloride is vulnerable to the same structural risks affecting older generic injectables. The American Society of Health-System Pharmacists has reported shortages of injectable oncology products when manufacturing disruptions, raw-material constraints, or limited supplier capacity reduce availability (American Society of Health-System Pharmacists, n.d.).
Key risks include:
- Limited supplier economics. Low prices can discourage investment in redundant production lines.
- Sterile manufacturing complexity. A single facility problem can remove a meaningful share of supply.
- Cytotoxic containment requirements. Facilities must meet specialized occupational and environmental controls.
- Hospital inventory policies. Buyers may maintain limited stock because of expiration and storage constraints.
- Global sourcing exposure. API and finished-product supply may cross multiple jurisdictions.
- Regulatory remediation. Warning letters, recalls, or manufacturing restrictions can produce abrupt shortages.
These factors create a market with low patent risk but meaningful execution risk.
Which companies are positioned in the daunorubicin market?
The competitive field consists mainly of generic injectable manufacturers, distributors, and hospital suppliers. Manufacturer participation can change as companies discontinue low-margin products or transfer applications.
The most commercially relevant company types are:
- Large generic manufacturers with sterile injectable portfolios
- Specialty oncology suppliers
- Contract manufacturers with cytotoxic containment
- Hospital-focused distributors
- Branded oncology companies selling differentiated daunorubicin combinations
Jazz Pharmaceuticals is relevant through Vyxeos, not as a standard generic daunorubicin supplier. Its product competes in a higher-value segment with a different regulatory and clinical profile.
What generic launch scenarios exist?
Because standard daunorubicin hydrochloride is already generic, future launch scenarios relate to new suppliers or differentiated products.
Base case
Existing suppliers maintain approval and hospitals continue purchasing through contracts. Revenue remains stable to modestly lower, with periodic shortages.
Upside case
A new manufacturer enters with reliable supply, captures hospital contracts, and benefits from a temporary shortage affecting incumbent suppliers. This can increase volume but usually produces limited long-term pricing power.
Downside case
One or more suppliers exit, manufacturing quality problems restrict supply, or API availability deteriorates. Hospitals experience allocation, and prices rise temporarily. The market may become more concentrated without becoming more profitable over the long term.
Differentiated-product case
A new liposomal, fixed-ratio, or targeted delivery product obtains approval. Such a product could command a premium, but it would compete through clinical benefit and regulatory differentiation rather than through the standard generic vial.
How strong is the patent estate for daunorubicin hydrochloride?
The patent estate is weak for the base drug and potentially stronger only for modified delivery systems or combination products.
| Dimension |
Strength |
| Base molecule |
Very weak |
| Standard injection |
Weak |
| New formulation |
Potentially moderate to strong |
| Liposomal delivery |
Product-specific and potentially meaningful |
| Fixed-ratio combination |
Potentially meaningful |
| Manufacturing know-how |
Moderate operational barrier |
| Regulatory exclusivity |
None expected for the mature generic product |
The commercial moat is therefore manufacturing execution, not patent ownership.
What is the investment and licensing outlook?
Licensing opportunities for standard daunorubicin hydrochloride are limited. A license would make more sense for:
- A novel liposomal formulation
- A fixed-ratio leukemia combination
- A targeted delivery system
- A safer anthracycline analog
- A regional sterile injectable supply agreement
- A manufacturing technology that lowers contamination or cardiotoxicity risk
The base generic product can support portfolio revenue for a hospital-products manufacturer but is unlikely to justify a standalone licensing premium. Investors should assess supply continuity, manufacturing utilization, tender wins, and product concentration rather than patent life.
Key Takeaways
- Daunorubicin hydrochloride is a mature generic anthracycline used mainly in acute myeloid leukemia and acute lymphoblastic leukemia.
- The standard injectable product has no meaningful remaining composition-of-matter exclusivity.
- There is no major patent-expiration event or Paragraph IV litigation expected to reshape the base market.
- Revenue is difficult to isolate because manufacturers report it within broader generic oncology portfolios.
- Volume is clinically durable, while pricing and margins remain under pressure.
- Supply shortages, sterile manufacturing failures, and supplier exits are more important than patent risk.
- CPX-351/Vyxeos is the principal differentiated daunorubicin product, but it is not interchangeable with standard daunorubicin hydrochloride injection.
- The strongest commercial opportunities involve delivery systems, fixed-ratio combinations, or reliable sterile manufacturing rather than the legacy molecule.
FAQs
Is daunorubicin hydrochloride still commercially important?
Yes. Its commercial value is modest compared with newer oncology products, but it remains clinically important in established leukemia induction and combination regimens.
Is daunorubicin hydrochloride interchangeable with Vyxeos?
No. Vyxeos is a liposomal fixed-ratio combination of daunorubicin and cytarabine. It has separate clinical, regulatory, dosing, and manufacturing characteristics.
Can a generic manufacturer obtain a new patent for daunorubicin hydrochloride?
A new patent cannot restore protection to the old molecule. Patent opportunities may exist for a genuinely novel formulation, delivery method, combination, or manufacturing process.
Does daunorubicin hydrochloride face biosimilar competition?
No. Daunorubicin hydrochloride is a small-molecule drug, so competition proceeds through generic drug applications rather than biosimilar applications.
What is the main commercial risk for daunorubicin hydrochloride?
The main risk is supply disruption caused by low-margin economics and limited sterile injectable manufacturing capacity. Patent erosion is no longer the primary risk.
References
-
American Society of Health-System Pharmacists. (n.d.). Drug shortages: Daunorubicin injection. ASHP Drug Shortage Center.
-
Jazz Pharmaceuticals. (2016). Jazz Pharmaceuticals completes acquisition of Celator Pharmaceuticals. Jazz Pharmaceuticals plc.
-
U.S. Food and Drug Administration. (n.d.-a). Daunorubicin hydrochloride injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.-b). Vyxeos: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.-c). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
